| Year |
Citation |
Score |
| 2024 |
Song IW, Washington M, Leynes C, Hsu J, Rayavara K, Bae Y, Haelterman N, Chen Y, Jiang MM, Drelich A, Tat V, Lanza DG, Lorenzo I, Heaney JD, Tseng CK, et al. Generation of a humanized mAce2 and a conditional hACE2 mouse models permissive to SARS-COV-2 infection. Mammalian Genome : Official Journal of the International Mammalian Genome Society. PMID 38488938 DOI: 10.1007/s00335-024-10033-8 |
0.306 |
|
| 2022 |
Fisher T, Gluck A, Narayanan K, Kuroda M, Nachshon A, Hsu JC, Halfmann PJ, Yahalom-Ronen Y, Tamir H, Finkel Y, Schwartz M, Weiss S, Tseng CK, Israely T, Paran N, et al. Parsing the role of NSP1 in SARS-CoV-2 infection. Cell Reports. 110954. PMID 35671758 DOI: 10.1016/j.celrep.2022.110954 |
0.376 |
|
| 2022 |
Fisher T, Gluck A, Narayanan K, Kuroda M, Nachshon A, Hsu JC, Halfmann PJ, Yahalom-Ronen Y, Finkel Y, Schwartz M, Weiss S, Tseng CK, Israely T, Paran N, Kawaoka Y, et al. Parsing the role of NSP1 in SARS-CoV-2 infection. Biorxiv : the Preprint Server For Biology. PMID 35313595 DOI: 10.1101/2022.03.14.484208 |
0.371 |
|
| 2021 |
Chan CEZ, Seah SGK, Chye H, Massey S, Torres M, Lim APC, Wong SKK, Neo JJY, Wong PS, Lim JH, Loh GSL, Wang D, Boyd-Kirkup JD, Guan S, Thakkar D, ... ... Tseng CK, et al. The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. Plos One. 16: e0253487. PMID 34161386 DOI: 10.1371/journal.pone.0253487 |
0.308 |
|
| 2021 |
Vatansever EC, Yang KS, Drelich AK, Kratch KC, Cho CC, Kempaiah KR, Hsu JC, Mellott DM, Xu S, Tseng CK, Liu WR. Bepridil is potent against SARS-CoV-2 in vitro. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 33597253 DOI: 10.1073/pnas.2012201118 |
0.329 |
|
| 2020 |
Curreli F, Victor SMB, Ahmed S, Drelich A, Tong X, Tseng CK, Hillyer CD, Debnath AK. Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection . Mbio. 11. PMID 33310780 DOI: 10.1128/mBio.02451-20 |
0.321 |
|
| 2020 |
Li W, Chen C, Drelich A, Martinez DR, Gralinski LE, Sun Z, Schäfer A, Kulkarni SS, Liu X, Leist SR, Zhelev DV, Zhang L, Kim YJ, Peterson EC, Conard A, ... ... Tseng CK, et al. Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America. PMID 33139569 DOI: 10.1073/pnas.2010197117 |
0.314 |
|
| 2020 |
Chen WH, Tao X, Agrawal AS, Algaissi A, Peng BH, Pollet J, Strych U, Bottazzi ME, Hotez PJ, Lustigman S, Du L, Jiang S, Tseng CK. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine. PMID 33039209 DOI: 10.1016/j.vaccine.2020.09.061 |
0.312 |
|
| 2020 |
Chen WH, Tao X, Agrawal A, Algaissi A, Peng BH, Pollet J, Strych U, Bottazzi ME, Hotez PJ, Lustigman S, Du L, Jiang S, Tseng CK. Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Alum Induces Protective Immunity and Reduces Immune Enhancement. Biorxiv : the Preprint Server For Biology. PMID 32511385 DOI: 10.1101/2020.05.15.098079 |
0.316 |
|
| 2020 |
Xing J, Shankar R, Drelich A, Paithankar S, Chekalin E, Dexheimer T, Rajasekaran S, Tseng CK, Chen B. Reversal of Infected Host Gene Expression Identifies Repurposed Drug Candidates for COVID-19. Biorxiv : the Preprint Server For Biology. PMID 32511305 DOI: 10.1101/2020.04.07.030734 |
0.305 |
|
| 2020 |
Algaissi A, Agrawal AS, Hashem AM, Tseng CK. Quantification of the Middle East Respiratory Syndrome-Coronavirus RNA in Tissues by Quantitative Real-Time RT-PCR. Methods in Molecular Biology (Clifton, N.J.). 2099: 99-106. PMID 31883090 DOI: 10.1007/978-1-0716-0211-9_8 |
0.335 |
|
| 2017 |
Wang Y, Tai W, Yang J, Zhao G, Sun S, Tseng CK, Jiang S, Zhou Y, Du L, Gao J. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. Human Vaccines & Immunotherapeutics. 0. PMID 28277821 DOI: 10.1080/21645515.2017.1296994 |
0.304 |
|
| 2016 |
Tai W, Zhao G, Sun S, Guo Y, Wang Y, Tao X, Tseng CK, Li F, Jiang S, Du L, Zhou Y. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology. 499: 375-382. PMID 27750111 DOI: 10.1016/J.Virol.2016.10.005 |
0.349 |
|
| 2015 |
Tao X, Garron T, Agrawal AS, Algaissi A, Peng BH, Wakamiya M, Chan TS, Lu L, Du L, Jiang S, Couch RB, Tseng CK. Characterization and Demonstration of value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. Journal of Virology. PMID 26446606 DOI: 10.1128/Jvi.02009-15 |
0.349 |
|
| 2015 |
Jiang S, Tao X, Xia S, Garron T, Yu F, Du L, Lu L, Tseng CK. Intranasally administered peptidic viral fusion inhibitor protected hDPP4 transgenic mice from MERS-CoV infection The Lancet. 386: S44. DOI: 10.1016/S0140-6736(15)00625-X |
0.301 |
|
| Show low-probability matches. |